Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

Bone Marrow Transplantation

Volumn 32, Issue 6, 2003, Pages 549-556

  Burke, J M ^a   Caron, P C ^a   Papadopoulos, E B ^a   Divgi, C R ^a   Sgouros, G ^a   Panageas, K S ^a   Finn, R D ^a   Larson, S M ^a   O'Reilly, R J ^a   Scheinberg, D A ^a   Jurcic, J G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute myelocytic leukemia; Chronic myeloid; Leukemia; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

ALLOPURINOL; BUSULFAN; CD33 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DIPHENHYDRAMINE; GLYCOPROTEIN; HYDROXYUREA; IMMUNOGLOBULIN G2A; IMMUNOSUPPRESSIVE AGENT; IODINE 131; LUGOL; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY M 195; PARACETAMOL; POTASSIUM PERCHLORATE; RADIOISOTOPE; RECOMBINANT ANTIBODY; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASCITES; BODY BURDEN; BODY WEIGHT DISORDER; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CELL DESTRUCTION; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DOSE RESPONSE; DOSIMETRY; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DYSPNEA; FEASIBILITY STUDY; FEVER; FLUSHING; FREQUENCY ANALYSIS; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HEPATOMEGALY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMAGING SYSTEM; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL PNEUMONIA; ISOTOPE LABELING; LEUKEMIA CELL; LEUKEMIA REMISSION; LIVER; LIVER TOXICITY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROTEIN TARGETING; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RELATIVE; RIGOR; SCINTILLATION CAMERA; SPLEEN; STANDARD; SURVIVAL TIME; TIME; URTICARIA; VEIN OCCLUSION; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; RADIATION DOSAGE; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 10744233589     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704201     Document Type: Article

References (44)

1. Socie G, Clift RA, Blaise D et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569-3574.
2. Stockerl-Goldstein KE, Blume KG. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Thomas ED, Blume KG, Forman SJ (eds.). Hematopoietic Cell Transplantation, 2nd edn. Blackwell Science, Inc.: Oxford, 1999; pp. 823-834.
3. Clift RA, Storb R. Marrow transplantation for CML: The Seattle experience. Bone Marrow Transplant 1996; 17 (Suppl. 3): S1-S3.
4. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17(Suppl. 3): S5-S6.
5. Gratwohl A, Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17(Suppl. 3): S7-S9.
6. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
7. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
8. Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838-843.
9. Geller RB, Saral R, Piantadosi S et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989; 73: 2209-2218.
10. Essell JH, Thompson JM, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784-2788.
11. Biggs JC, Szer J, Crilley P et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992; 80: 1352-1357.
12. Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
13. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
14. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
15. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263-2268.
16. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81: 2187-2193.
17. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
18. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77: 1660-1665.
19. Bieri S, Helg C, Chapuis B, Miralbell R. Total body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys 2001; 49: 1071-1077.
20. Appelbaum FR, Matthews DC, Eary JF et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829-833.
21. Matthews DC, Appelbaum FR, Eary JF et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237-1247.
22. Matthews DC, Appelbaum FR, Eary JF et al. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission. Blood 1996; 88 (Suppl. 1): 142a (Abstr. 556).
23. Bunjes D, Buchmann I, Duncker C et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001; 98: 565-572.
24. Tanimoto M, Scheinberg DA, Cordon-Cardo C et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 1989; 3: 339-348.
25. Scheinberg DA, Lovett D, Divgi CR et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478-490.
26. Co MS, Avdalovic NM, Caron PC et al. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992; 148: 1149-1154.
27. Caron PC, Jurcic JG, Scott AM et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994; 83: 1760-1768.
28. Schwartz MA, Lovett DR, Redner A et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11: 294-303.
29. Jurcic JG, Caron PC, Nikula TK et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995; 55(Suppl. 23): 5908s-5910s.
30. Caron PC, Co MS, Bull MK et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52: 6761-6767.
31. Nikula TK, Bocchia M, Curcio MJ et al. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 1995; 32: 865-872.
32. Forman SJ, Blume KG, Krance RA et al. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone. Transplant Proc 1987; 19 (1 Part 3): 2605-2607.
33. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
34. Society of Nuclear Medicine. MIRD Primer for Absorbed Dose Calculations. Society of Nuclear Medicine: New York, NY; 1988.
35. Scheinberg DA, Straus DJ, Yeh SD et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 1990; 8: 792-803.
36. National Cancer Institute. Common toxicity criteria version 2.0. 1999: http://ctep.cancer.gov/reporting/ctc.html.
37. Jones RJ, Lee KS, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
38. Blaise D, Maraninchi D, Michallet M et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001; 97: 3669-3671.
39. Clift RA, Radich J, Appelbaum FR et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999; 94: 3960-3962.
40. Ringden O, Remberger M, Ruutu T et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196-2201.
41. Champlin R, Khouri I, Anderlini P et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 2001; 27 (Suppl. 2): S13-S22.
42. Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083-1090.
43. Scheinberg DA, Strand M. Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res 1983; 43: 265-272.
44. Jurcic JG, Divgi CR, McDevitt MR et al. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. Proc Am Soc Clin Oncol 2000; 19: 8a (Abstr. 24).